Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Phase III Trial Of One Vs. Two Years Of Maintenance Olaparib, With Or Without Bevacizumab, In Patients With BRCA1/2 Mutated Or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response To First Line Platinum Based Chemotherapy
Scottsdale/Phoenix, AZ
Rochester, MN
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5\'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
-
Catalina-2: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
-
MC1963 Folate Receptor Alpha Dendritic Cells (FRalphaDCs) Or Placebo For Patients With Advanced Stage Ovarian Cancer, A Phase II Double-Blind Randomized Clinical Trial (FAROUT)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to determine whether vaccination with folate receptor alpha dendritic cells (FRalphaDCs) given to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer can delay or prevent cancer recurrence, when compared with a placebo. FRalphaDCs are a vaccine made from patients' white blood cells that have been cultured in the laboratory to induce immune responses to the cancer.
Closed for Enrollment
-
A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, The Combination Of Cediranib/Olaparib And The Combination Of Olaparib/Wee1 Inhibitor AZD1775 In Women With Recurrent, Persistent Or Metastatic Endometrial Cancer (EEC)
Scottsdale/Phoenix, AZ
Eau Claire, WI
Rochester, MN
The purpose of this randomized phase II trial study is to determine how well olaparib, cediranib maleate, and Week 1 inhibitor AZD1775 work in treating patients with endometrial cancer that has come back, does not respond to treatment, or has spread to other places in the body. Olaparib, cediranib maleate, and Wee1 inhibitor AZD1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
-
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib To Physicians Choice Of Cabozantinib Or Vandetanib In Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate the safety and effectiveness of Selpercatinib, compared to a standard treatment, in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
-
A Phase 1/2 Study Of Oral LOXO-292 In Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, And Other Tumors With RET Activation (LIBRETTO-001)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
-
A Randomized Double-Blind Phase III Trial Of EC145 Combined With Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) Compared To Pegylated Liposomal Doxorubicin Alone, In Participants With Platinum-Resistant Ovarian Cancer
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to compare the progression-free survival in women who have platinum-resistant ovarian cancer, who receive combination therapy with EC145 and pegylated liposomal doxorubicin (EC145+PLD) with those who receive PLD alone.
-
An Open-Label, Single-Arm, Multicenter, Phase 2 Trial Of Lenvatinib For The Treatment Of Anaplastic Thyroid Cancer (ATC)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate response, survival, safety, and tolerability of treatment with lenvatinib for patients who have anaplastic thyroid cancer.
-
Expanded Access For The Treatment Of Cancers With Rearranged During Transfection (RET) Activation
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to provide expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.
.